Reaction Details | |||
---|---|---|---|
Report a problem with these data | |||
Target | Tyrosine-protein kinase Lck | ||
Ligand | BDBM8797 | ||
Substrate/Competitor | n/a | ||
Meas. Tech. | ChEBML_221313 | ||
IC50 | 93±n/a nM | ||
Citation | Borhani, DW; Calderwood, DJ; Friedman, MM; Hirst, GC; Li, B; Leung, AK; McRae, B; Ratnofsky, S; Ritter, K; Waegell, W A-420983: a potent, orally active inhibitor of lck with efficacy in a model of transplant rejection. Bioorg Med Chem Lett14:2613-6 (2004) [PubMed] Article | ||
More Info.: | Get all data from this article, Assay Method | ||
Tyrosine-protein kinase Lck | |||
Name: | Tyrosine-protein kinase Lck | ||
Synonyms: | 2.7.10.2 | LCK | LCK_HUMAN | LSK | Leukocyte C-terminal Src kinase | Lymphocyte cell-specific protein-tyrosine kinase | Lymphocyte-specific protein tyrosine kinase | P56-LCK | Protein YT16 | Proto-oncogene Lck | Proto-oncogene tyrosine-protein kinase LCK | Src/Lck kinase | T cell-specific protein-tyrosine kinase | ||
Type: | n/a | ||
Mol. Mass.: | 57987.83 | ||
Organism: | Homo sapiens (Human) | ||
Description: | P06239 | ||
Residue: | 509 | ||
Sequence: |
| ||
BDBM8797 | |||
n/a | |||
Name | BDBM8797 | ||
Synonyms: | CHEMBL297363 | N-(4-{4-amino-1-[4-(4-methylpiperazin-1-yl)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl}-2-methoxyphenyl)benzamide | Pyrazolo[3,4-d]pyrimidine 5 | ||
Type | Small organic molecule | ||
Emp. Form. | C30H36N8O2 | ||
Mol. Mass. | 540.6592 | ||
SMILES | COc1cc(ccc1NC(=O)c1ccccc1)-c1nn([C@H]2CC[C@@H](CC2)N2CCN(C)CC2)c2ncnc(N)c12 |r,wU:20.21,wD:23.28,(.85,5.16,;-.29,6.2,;-1.75,5.73,;-2.08,4.23,;-3.55,3.76,;-4.69,4.8,;-4.36,6.3,;-2.89,6.77,;-2.56,8.27,;-1.1,8.74,;.04,7.7,;-.77,10.25,;-1.86,11.33,;-1.46,12.82,;.02,13.22,;1.12,12.14,;.72,10.65,;-4.03,2.3,;-3.12,1.05,;-4.03,-.2,;-3.55,-1.66,;-2.06,-2.04,;-1.64,-3.52,;-2.72,-4.63,;-4.21,-4.25,;-4.63,-2.76,;-2.3,-6.11,;-3.34,-7.24,;-2.87,-8.71,;-1.37,-9.04,;-.91,-10.51,;-.33,-7.91,;-.8,-6.44,;-5.49,.28,;-6.82,-.49,;-8.16,.28,;-8.16,1.82,;-6.82,2.59,;-6.82,4.13,;-5.49,1.82,)| | ||
Structure |